Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.

被引：0
|
作者：
Burotto, Mauricio
Powles, Thomas
Escudier, Bernard
Apolo, Andrea B.
Bourlon, Maria Teresa
Shah, Amishi Yogesh
Suarez, Cristina
Porta, Camillo
Barrios, Carlos H.
Richardet, Martin
Gurney, Howard
Kessler, Elizabeth R.
Tomita, Yoshihiko
Bedke, Jens
George, Saby
Scheffold, Christian
Wang, Peter
Fedorov, Viktor
Motzer, Robert J.
Choueiri, Toni K.
机构：
[1] Bradford Hill Clin Res Ctr, Santiago, Chile
[2] Barts Canc Ctr, London, England
[3] Royal Free London NHS Fdn Trust, London, England
[4] Gustave Roussy, Villejuif, France
[5] NCI, Ctr Canc Res, NIH, Bethesda, MD USA
[6] Inst Nacl Ciencias Med Nutr, Mexico City, Mexico
[7] MD Anderson Canc Ctr, Houston, TX USA
[8] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[9] Univ Pavia, Pavia, Italy
[10] Ctr Pesquisa Oncol, Porto Alegre, Brazil
[11] Inst Oncol Cordoba, dn Richardet Longo, Cordoba, Argentina
[12] Westmead Hosp, Sydney, NSW, Australia
[13] Macquarie Univ, Sydney, NSW, Australia
[14] Univ Colorado, Canc Ctr, Anschutz Med Campus, Aurora, CO USA
[15] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan
[16] Eberhard Karls Univ Tubingen, Tubingen, Germany
[17] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[18] Exelixis Inc, Alameda, CA USA
[19] Bristol Myers Squibb, Princeton, NJ USA
[20] Mem Sloan Kettering Canc Ctr, New York, NY USA
[21] Brigham & Womens Hosp, Lank Ctr Genitourinary Oncol, Dana Farber Canc Inst, Boston, MA USA
[22] Harvard Med Sch, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
603
引用
收藏
页数：1
相关论文
共 50 条
  • [31] First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
    Janjigian, Yelena Y.
    Ajani, Jaffer A.
    Moehler, Markus
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Wyrwicz, Lucjan
    Yamaguchi, Kensei
    Cleary, James M.
    Elimova, Elena
    Karamouzis, Michalis
    Bruges, Ricardo
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshi
    Tehfe, Mustapha
    Zander, Thomas
    Kowalyszyn, Ruben
    Pazo-Cid, Roberto
    Schenker, Michael
    Feeny, Kynan
    Wang, Rui
    Lei, Ming
    Chen, Clara
    Nathani, Raheel
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17) : 2012 - 2020
  • [32] A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).
    Choueiri, Toni K.
    Apolo, Andrea B.
    Powles, Thomas
    Escudier, Bernard
    Aren, Osvaldo Rudy
    Shah, Amishi
    Kessler, Elizabeth Riley
    Hsieh, James J.
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
    Motzer, Robert
    Rini, Brian, I
    McDermott, David F.
    Frontera, Osvaldo Aren
    Hammers, Hans J.
    Carducci, Michael A.
    Salman, Pamela
    Escudier, Bernard
    Beuselinck, Benoit
    Amin, Asim
    Porta, Camillo
    George, Saby
    Neiman, Victoria
    Bracarda, Sergio
    Tykodi, Scott S.
    Barthelemy, Philippe
    Leibowitz-Amit, Raya
    Plimack, Elizabeth R.
    Oosting, Sjoukje F.
    Redman, Bruce
    Melichar, Bohusiav
    Powles, Thomas
    Nathan, Paul
    Oudard, Stephan
    Pook, David
    Choueiri, Toni K.
    Donskov, Frede
    Grimm, Marc-Oliver
    Gurney, Howard
    Heng, Daniel Y. C.
    Kollmannsberger, Christian K.
    Harrison, Michael R.
    Tamita, Yoshihiko
    Duran, Ignacio
    Gruenwold, Viktor
    McHenry, M. Brent
    Mekan, Sabeen
    Tannir, Nizar M.
    LANCET ONCOLOGY, 2019, 20 (10): : 1370 - 1385
  • [34] Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012
    Antonia, S.
    Gettinger, S.
    Borghaei, H.
    Goldman, J. W.
    Brahmer, J.
    Ready, N.
    Gerber, D.
    Chow, L.
    Juergens, R.
    Laurie, S.
    Shepherd, F.
    Li, X.
    Li, A.
    Geese, W.
    Hellmann, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S458 - S458
  • [35] Increasing combination possibilities for first-line treatment of metastatic clear cell renal cell carcinoma with nivolumab plus cabozantinib Results of the CheckMate-9ER trial
    Oing, Christoph
    Bokemeyer, Carsten
    ONKOLOGE, 2021, 27 (02): : 168 - 171
  • [36] Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.
    Powles, Thomas
    Choueiri, Toni K.
    Burotto, Mauricio
    Escudier, Bernard
    Bourlon, Maria Teresa
    Shah, Amishi Yogesh
    Suarez, Cristina
    Hamzaj, Alketa
    Porta, Camillo
    Hocking, Christopher
    Kessler, Elizabeth R.
    Gurney, Howard
    Tomita, Yoshihiko
    Bedke, Jens
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Apolo, Andrea B.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [37] Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial
    Apolo, Andrea B.
    Powles, Thomas
    Escudier, Bernard
    Burotto, Mauricio
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    EUROPEAN JOURNAL OF CANCER, 2022, 177 : 63 - 71
  • [38] Plain language summary of quality of life in CheckMate 9ER: Cabozantinib plus nivolumab in advanced renal cell carcinoma (OCT, 10.1080/14796694.2024.2415786, 2024)
    Cella, David
    Motzer, Robert J.
    Suarez, Cristina
    Blum, Steven, I
    Ejzykowicz, Flavia
    Hamilton, Melissa
    Wallace, Joel F.
    Simsek, Burcin
    Zhang, Joshua
    Ivanescu, Cristina
    Choueiri, Toni K.
    Apolo, Andrea B.
    FUTURE ONCOLOGY, 2024,
  • [39] JAVELIN renal 101: a phase 3 study of avelumab in combination with axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
    Choueiri, Toni K.
    Rini, Brian I.
    Cosgriff, Thomas
    Miyake, Hideaki
    Vogelzang, Nicholas J.
    Kannourakis, George
    Mariani, Mariangela
    Chiruzzi, Chiara
    Albiges, Laurence
    Haanen, John B.
    Larkin, James
    Atkins, Michael B.
    Schmidinger, Manuela
    Magazzu, Domenico
    Di Pietro, Alessandra
    Motzer, Robert J.
    BJU INTERNATIONAL, 2016, 118 : 29 - 30
  • [40] Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States
    Li, SiNi
    Li, JianHe
    Peng, LiuBao
    Li, YaMin
    Wan, XiaoMin
    FRONTIERS IN PHARMACOLOGY, 2021, 12
12345